skip to main content

United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2019 financial results before the market opens on Wednesday, October 30, 2019.

United Therapeutics will host a teleconference on Wednesday, October 30, 2019, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 7462119.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at https://ir.unither.com/events-presentations

Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-report-third-quarter-2019-financial-results-before-the-market-opens-on-wednesday-october-30-2019-300943486.html

SOURCE United Therapeutics Corporation

Recent Press Releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of...
Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug Administration (FDA) ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fireside chat...
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients...
Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, if approved by the U.S. Food and Drug Administration (FDA)Ralinepag combines potent receptor...
Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United...